SCHEMBL24697708

SCHEMBL24697708

CC1(C)COc2cc(Br)ccc2C(=O)N1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAT2 Q10469 1/20 0.44
TDP2 O95551 1/20 0.40
ALK Q9UM73 4/20 0.37
NTRK1 P04629 2/20 0.37
PIK3CD O00329 1/20 0.37
PIK3CA P42336 1/20 0.37
PIK3CB P42338 1/20 0.37
PIK3CG P48736 1/20 0.37
PBRM1 Q86U86 1/20 0.37
HTT P42858 2/20 0.36
PARP10 Q53GL7 1/20 0.36
PARP11 Q9NR21 1/20 0.36
MAP3K5 Q99683 1/20 0.36
TGM2 P21980 1/20 0.36
CES1 P23141 1/20 0.36
NR3C1 P04150 1/20 0.36
PGR P06401 1/20 0.36
AR P10275 1/20 0.36
HPGD P15428 2/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29295508 0.83 MGAT2 (0.44) MGAT2ALKNTRK1PIK3CDPIK3CB
SCHEMBL34463445 0.78 PGR (0.39) MGAT2HTTTGM2CES1NR3C1
SCHEMBL29640600 0.76 PBRM1 (0.40) TDP2PBRM1HTTMALT1HTR2A
SCHEMBL3456628 0.76 PBRM1 (0.40) TDP2PBRM1HTTMALT1HTR2A
SCHEMBL31619281 0.76 TDP2 (0.39) TDP2PARP10PARP11TGM2CES1
SCHEMBL8834065 0.74 HTR2A (0.47) PIK3CDPIK3CAPIK3CBPIK3CGPBRM1
SCHEMBL30512977 0.73 HTT (0.58) TDP2PIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL23160411 0.73 KDM4E (0.57) TDP2PBRM1HTTPARP10PARP11
SCHEMBL5344623 0.71 CA1 (0.41) TDP2PBRM1HTTPARP10PARP11
SCHEMBL24697545 0.71 PBRM1 (0.41) TDP2PBRM1HTTPARP10PARP11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 US disclosed
US-20240226115-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. 2024-07-11 US disclosed
WO-2022246179-A1 AXL INHIBITOR COMPOUNDS ARCUS BIOSCIENCES, INC. (US) 2022-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240226115-A1 AXL INHIBITOR COMPOUNDS AXL, BTK, MERTK MGAT2 2630/4885TDP2 4081/4885ALK 252/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.